Detalles de la búsqueda
1.
MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama.
BMC Cancer
; 23(1): 514, 2023 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37280528
2.
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC.
Int J Mol Sci
; 24(19)2023 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37833968
3.
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
BMC Med
; 20(1): 277, 2022 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031613
4.
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors.
BMC Med
; 20(1): 435, 2022 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36352411
5.
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
Future Oncol
; 18(12): 1485-1497, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114807
6.
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Lancet Oncol
; 22(9): 1265-1274, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391508
7.
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
BMC Med
; 19(1): 239, 2021 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34615542
8.
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
Cancer Immunol Immunother
; 69(12): 2599-2611, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32591861
9.
A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
BMC Med
; 18(1): 232, 2020 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32843031
10.
Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report.
J Clin Pharm Ther
; 45(6): 1511-1514, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893899
11.
Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Cancer Sci
; 110(5): 1665-1675, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30844110
12.
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Invest New Drugs
; 37(4): 731-737, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706337
13.
First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China.
Chin J Cancer Res
; 31(5): 749-758, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31814679
14.
LncRNA cancer susceptibility candidate 15 accelerates the breast cancer cells progression via miR-153-3p/KLF5 positive feedback loop.
Biochem Biophys Res Commun
; 506(4): 819-825, 2018 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30389133
15.
Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.
Proc Natl Acad Sci U S A
; 112(32): 9990-5, 2015 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26216950
16.
Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.
J BUON
; 23(5): 1402-1406, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570865
17.
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients.
Proc Natl Acad Sci U S A
; 110(52): 21083-8, 2013 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24324171
18.
A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.
Chin J Cancer Res
; 28(1): 12-8, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27041923
19.
[Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].
Zhonghua Jie He He Hu Xi Za Zhi
; 38(4): 261-6, 2015 Apr.
Artículo
en Zh
| MEDLINE | ID: mdl-26268231
20.
Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer.
Heliyon
; 10(2): e24796, 2024 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304763